SEC Form 4 · accession 0001209191-19-006630
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David T Howton
Officer — SVP, General Counsel
Period of report
Feb 1, 2019
Accepted (ET)
Feb 1, 2019 · 8:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2019 | M | 3,125 | $13.71 | A | 31,196 | D | |
| Common Stock | Feb 1, 2019 | M | 1,548 | $13.71 | A | 32,744 | D | |
| Common Stock | Feb 1, 2019 | M | 16,827 | $23.85 | A | 49,571 | D | |
| Common Stock | Feb 1, 2019 | S | 30,000 | $140.00 | D | 19,571 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $13.71 | Feb 1, 2019 | M | 3,125 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 3,125 | 6,965 | D |
| Stock Option (right to buy) | $13.71 | Feb 1, 2019 | M | 1,548 | D | Sep 19, 2016 | Sep 19, 2025 | Common Stock | 1,548 | 5,883 | D |
| Stock Option (right to buy) | $23.85 | Feb 1, 2019 | M | 16,827 | D | Nov 5, 2013 | Nov 5, 2022 | Common Stock | 16,827 | 116,405 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.